Similar Articles

Browse Main Topics:

Business
Computers & Electronics
Education & Reference
Entertainment & Leisure
Family & Home
Finance & Investment
Health
Internet
Pets & Animals
Science & Technology
Society, Politics & Culture
Sports & Recreation

Similar Articles

Chemistry World May 28, 2012 Sarah Houlton	HDL drug class struggling after latest flop The failure of dalcetrapib, a drug from Roche designed to raise HDL, or 'good', cholesterol, has turned the spotlight again on such drugs.
The Motley Fool December 1, 2009 Robert Steyer	Merck Makes a Mark on Good Cholesterol Can't profit from fighting bad lipoproteins? Start boosting the good ones.
The Motley Fool October 5, 2007 Brian Orelli	Merck's Next Blockbuster? Merck's cholesterol drug comes back from phase 2 testing with no side effects. Investors, take note.
The Motley Fool August 24, 2011 Brian Orelli	Can Roche and Merck Succeed Where Pfizer Failed? CETP inhibitors are lucrative but risky.
BusinessWeek November 24, 2010 Tom Randall	Merck May Have a Cholesterol Winner Merck told doctors at the American Heart Assn. annual meeting that new data showed its drug anacetrapib had reduced bad cholesterol by 40 percent while raising good cholesterol by an unprecedented 138 percent.
The Motley Fool December 4, 2006 Michael P. Cecil	Pfizer's Cholesterol-Drug Hopes Crumble In surprising and disappointing news, the pharma's promising new drug fails clinical trials. With Pfizer shares declining because of the bad news, is now a good time to buy?
Chemistry World January 2007 Derek Lowe	Opinion: In the Pipeline Here is a look at the recent failure of Pfizer's cholesterol drug, torcetrapib, and what it could mean for the future of pharmaceutical research.
The Motley Fool December 23, 2003 Arash Mostaghimi	The Cholesterol Wars Who will win the fight to save your arteries? Fortunately for our corpulent country, pharmaceutical companies want to unclog our arteries -- and lighten our wallets. But which pharma stock will add to most girth to a portfolio?
The Motley Fool December 30, 2003 Arash Mostaghimi	Turning Cholesterol Into Cash With 62 million Americans suffering from heart disease, it's a huge target for major drug makers.
The Motley Fool November 15, 2011 Brian Orelli	Good Data, Big Drug Market, but Still Risky Eli Lilly's evacetrapib is behind Roche and Merck.
BusinessWeek March 11, 2010 Ellen Gibson	The Quest to Boost Good Cholesterol Cleveland Clinic's Steven Nissen is again pursuing a drug that will attack plaque by raising HDL.
The Motley Fool August 30, 2007 Brian Orelli	Merck Tries to Stop the Flushing The FDA will review the pharma's new cholesterol drug. The biggest worry with getting CORDAPTIVE approved is probably not with its effectiveness, but with safety. Investors, take note.
BusinessWeek April 19, 2004 Catherine Arnst	Cholesterol: How Low Should It Be? New studies say as low as possible, but drugs aren't for everybody
American Family Physician January 15, 2001	Goals for Lowering Your Cholesterol Why is it important to have a normal cholesterol level?... What does the term "total cholesterol" mean?... Why is LDL called the "bad" cholesterol?... What are normal cholesterol levels?... How can I reduce my LDL and total cholesterol levels?... etc.
BusinessWeek March 11, 2010	Four Ways to Raise HDL Four different routes to raising good cholesterol.
American Family Physician March 1, 2002 Richard S. Safeer	Cholesterol Treatment Guidelines Update In addition to modifying current strategies of risk assessment, the new guidelines stress the importance of an aggressive therapeutic approach in the management of hypercholesterolemia...
BusinessWeek December 13, 2004 Kate Murphy	Cholesterol: The Bigger the Better Many doctors are convinced that getting a more thorough cholesterol test, one that identifies the types of LDL particles, can improve treatment and save lives.
The Motley Fool December 12, 2007 Brian Orelli	What's Merck Doing? With a nice solid pipeline Merck is on its way to its goal of double-digit EPS growth through 2010.
American Family Physician April 15, 2003	Cholesterol What is cholesterol?... Why is a high cholesterol level unhealthy?... When should I start having my cholesterol level checked?... Are there different kinds of cholesterol?... What can I do to improve my cholesterol level?... etc.
Pharmaceutical Executive December 1, 2010 Walter Armstrong	The Next Wave: Pharm Exec's 2011 Pipeline Report 42 of the best new drugs in development or parked at the FDA
HHMI Bulletin May 2011 Sarah C. P. Williams	The Next Statin Although clinicians have firmly established the link between cholesterol levels and heart disease, there are still more questions than answers when it comes to the nitty-gritty molecular details of this connection.
The Motley Fool September 24, 2010 Brian Orelli	Prepare for This $12 Billion Whoosh Pfizer's Lipitor is the top-selling cholesterol drug -- in fact, it's the top selling drug period -- but it'll start to see generic competition in a little over a year.
The Motley Fool May 20, 2009 Brian Orelli	Clinical Trial Positive, Stock Not So Much Isis and Genzyme hit a homer with their cholesterol drug, mipomersen, but they'll need another big play to win the game.
The Motley Fool November 16, 2009 Brian Orelli	Abbott Puts a Nail in Merck's Coffin There's a clear winner from the American Heart Association conference.
The Motley Fool January 27, 2004 David Nierengarten	Pfizer's Next Target? Esperion, swallowed by Pfizer last year, shares many similarities with Atherogenics. Investors in the latter, however, should not count on being acquired any time soon by a big pharmaceutical company.
The Motley Fool March 14, 2006 Brian Gorman	AstraZeneca's Heartening News A new study shows cholesterol drug Crestor's further potential. Will it help sales?
BusinessWeek July 21, 2003 Amy Barrett	A Bare-Knuckle Battle over Cholesterol Drugs If AstraZeneca's Crestor is approved, rivals' stepped-up pitches will focus on safety
American Family Physician January 15, 2002 Lori J. Mosca	Optimal Management of Cholesterol Levels and the Prevention of Coronary Heart Disease in Women Elevated levels of low-density lipoprotein cholesterol and triglycerides and low levels of high-density lipoprotein cholesterol are significant risk factors for coronary heart disease. Abundant data show inadequate utilization of lipid-lowering therapy in women...
The Motley Fool April 29, 2008 Brian Orelli	Merck's Recovery Flushed Down Merck's best hope at recovery fails approval by the FDA.
BusinessWeek July 26, 2004 Amy Barrett	Hooked On The Cash From Cholesterol Cholesterol-lowering drugs are massive moneyspinners. But can big pharmaceutical companies sidestep expiring patents?
Health January 2008 Jessica Snyder Sachs	What You Must Know About Your Cholesterol Many of us are in the danger zone, and we don't realize it. What can we start to do right now to change that?
Chemistry World May 2008 Derek Lowe	In the pipeline The controversy over cholesterol drug Vytorin has been going on for months. Surveying the wreckage, my first thought is: what a terrible shame the whole affair is.
Scientific American April 2005 Diane Martindale	Reactive Reasoning Is an inflammation protein the next cholesterol?
Managed Care April 2004 Jack McCain	Statin Therapy: More Than Meets the Eye? Statin selection has just become more complicated. Will physicians be diverted from interventions that may be less costly and just as effective?
Pharmaceutical Executive October 1, 2006 Rob Scott	Thoughtleader: Life After Lipitor A conversation with a former Pfizer executive who "launched the world's best-selling drug."
The Motley Fool April 2, 2008 Michael P. Cecil	Irrational Exuberance for Vytorin and Zetia? Drugmakers Merck and Schering-Plough certainly hoped data from the Enhance study would enhance the value and status of their blockbuster cholesterol-fighting drugs Zetia and Vytorin -- but its results did quite the opposite.
The Motley Fool November 22, 2010 Brian Orelli	Let's Call It a Partial Victory Merck's Vytorin works better than a placebo. Unfortunately, it may be too little and too late to do anything about the sales cut that Vytorin has taken over the past few years.
Chemistry World August 23, 2007 Richard Van Noorden	How Good Cholesterol Turns Bad Chemists have peered into the depths of HDL, which protects against heart disease, to explain why it can become harmful. The research may also suggest an explanation for the near-billion-dollar failure of Pfizer's blockbuster heart drug, torcetrapib, in recent clinical trials.
American Family Physician January 15, 2001 Michael A. Crouch	Effective Use of Statins to Prevent Coronary Heart Disease Primary and secondary prevention trials have shown that use of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors (also known as statins) to lower an elevated low-density lipoprotein level can substantially reduce coronary events and death from coronary heart disease...
The Motley Fool January 15, 2008 Brian Orelli	No Enhance-ment From Zetia Merck and Schering report bad news, but how much will it affect sales? Investors, take note.
The Motley Fool January 17, 2008 Michael P. Cecil	2 Sources of Trouble for Vytorin You know that a drug study has gone very, very bad when you can't find out its results without a congressional inquiry.
The Motley Fool August 5, 2010 Brian Orelli	Blockbuster Efficacy! Not-So-Blockbuster Safety! Isis and Genzyme's wonder drug has not-so-wonderful side effects. Still.
American Family Physician December 15, 2000 Alan J. Garber	Attenuating Cardiovascular Risk Factors in Patients with Type 2 Diabetes All cardiovascular risk factors except smoking are more prevalent in patients with type 2 diabetes. In addition to exercise, weight control, aspirin therapy and blood pressure control, therapy to modify lipid profiles is usually necessary...
The Motley Fool May 27, 2011 Brian Orelli	AIM-HIGH? These Drugmakers Better Duck. A government study on cholesterol drugs hurts Abbott and Merck.
BusinessWeek March 6, 2006 Amy Barrett	Merck: Out Of The Ivory Tower Merck's pragmatic strategy includes tweaking the vitamin niacin to make it a blockbuster.
The Motley Fool June 27, 2005 Brian Gorman	Pfizer's Controversial Pairing The pharmaceutical's strategy of combining an experimental medicine with Lipitor will likely come under increasing fire. Investors, take note.
The Motley Fool April 18, 2011 Brian Orelli	Up 95%! No Anchor Holding Amarin Down The second phase 3 trial of AMR101 deemed a success.
The Motley Fool December 4, 2008 Brian Orelli	Pfizer Blows Statin Smoke Pfizer presents some mildly persuasive numbers to try to win back customers for Lipitor.
Managed Care November 2004 Martin Sipkoff	OTC Status for Low-Dose Lovastatin Would Have Widespread Implications The FDA stands poised to approve OTC low-dose statins, following a similar change in United Kingdom.
Pharmaceutical Executive December 1, 2006	Pipeline 32 compounds that are the early fruit of pharma's investment in targeted drug design.